Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.44 |
| ▸ | CCR2 | P41597 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16390663 | 0.87 | EPHX2 (0.53) | GRM5THRBHPGDEPHX2KMT2A | |
| SCHEMBL990289 | 0.87 | EPHX2 (0.53) | GRM5THRBHPGDEPHX2KMT2A | |
| SCHEMBL990340 | 0.83 | L3MBTL1 (0.59) | GRM5L3MBTL1KMT2ANPC1RAB9A | |
| SCHEMBL991436 | 0.82 | KDM4E (0.49) | GRM5THRBHPGDKMT2ARAB9A | |
| SCHEMBL3772781 | 0.82 | KDM4E (0.49) | GRM5THRBHPGDKMT2ARAB9A | |
| SCHEMBL990846 | 0.81 | NPC1 (0.46) | GRM5EPHX2KMT2ANPC1 | |
| SCHEMBL4722043 | 0.81 | PLAAT3 (0.44) | GRM5L3MBTL1THRBHPGDEPHX2 | |
| SCHEMBL990794 | 0.80 | MDM2 (0.41) | GRM5L3MBTL1THRBHPGDEPHX2 | |
| SCHEMBL990909 | 0.80 | GRM5 (0.45) | GRM5L3MBTL1THRBHPGDEPHX2 | |
| SCHEMBL4656000 | 0.79 | HPGD (0.55) | GRM5L3MBTL1HPGDKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2826478-A1 | COMBINATIONS COMPRISING MGLUR MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | Novartis AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| EP-2320892-A2 | COMBINATION PRODUCTS | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| EP-2272509-A1 | New Uses of metabotropic glutamate receptors | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| EP-2211859-A2 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-20100099682-A1 | ACETYLENE DERIVATIVES | NOVARTIS AG | 2010-04-22 | — | — | US | disclosed |
| US-7696379-B2 | Acetylene derivatives | NOVARTIS AG (CH) | 2010-04-13 | — | — | US | disclosed |
| WO-2010000763-A2 | COMBINATION PRODUCTS | NOVARTIS AG (CH) | 2010-01-07 | — | — | WO | disclosed |
| WO-2009047296-A2 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS FOR THE TREATMENT OP PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2009-04-16 | — | — | WO | disclosed |
| US-20080214673-A1 | Acetylene Derivatives | NOVARTIS AG (CH) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099682-A1 | ACETYLENE DERIVATIVES | NAT1, NAT10, F12 | GRM5 3794/4885CCR2 2085/4885L3MBTL1 4519/4885 |
| US-20080214673-A1 | Acetylene Derivatives | NAT1, NAT10, F12 | GRM5 3794/4885CCR2 2085/4885L3MBTL1 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.